Controlled Trial on the Short-term Effects of Sacubitril/Valsartan Therapy on Cardiac Oxygen Consumption and Efficiency of Cardiac Work in Patients With NYHA II-III Heart Failure and Reduced Systolic Function Using 11C-acetate Positron Emission Tomography and Echocardiography

Trial Profile

Controlled Trial on the Short-term Effects of Sacubitril/Valsartan Therapy on Cardiac Oxygen Consumption and Efficiency of Cardiac Work in Patients With NYHA II-III Heart Failure and Reduced Systolic Function Using 11C-acetate Positron Emission Tomography and Echocardiography

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 03 Aug 2018

At a glance

  • Drugs Sacubitril/valsartan (Primary) ; Valsartan
  • Indications Chronic heart failure
  • Focus Therapeutic Use
  • Acronyms TurkuPET
  • Sponsors Novartis Pharmaceuticals
  • Most Recent Events

    • 23 Jul 2018 Planned End Date changed from 31 Aug 2019 to 2 Sep 2019.
    • 23 Jul 2018 Planned primary completion date changed from 31 Aug 2019 to 4 Feb 2019.
    • 23 Jul 2018 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top